Limits...
Qualitative assessment of innovations in healthcare provision.

Porzsolt F, Ghosh AK, Kaplan RM - BMC Health Serv Res (2009)

Bottom Line: From the patient's perspective, benefit resulting from an innovation can be confirmed only in a later phase of development.Potential for patient benefit is always uncertain during early stages of innovations.This uncertainty decreases with increasing information on the effects of the innovation.

View Article: PubMed Central - HTML - PubMed

Affiliation: Clinical Economics, University of Ulm, Frauensteige 6, 89075 Ulm, Germany. franz.porzsolt@uniklinik-ulm.de

ABSTRACT

Background: The triad of quality, innovation and economic restraint is as important in health care as it is in the business world. There are many proposals for the assessment of quality and of economic restraints in health care but only a few address assessment of innovations. We propose a strategy and new structures to standardize the description of health care innovations and to quantify them.

Discussion: Strategy and structure are based on the assumption that in the early phase of an innovation only data on the feasibility and possibly on the efficacy or effectiveness of an innovation can be expected. From the patient's perspective, benefit resulting from an innovation can be confirmed only in a later phase of development. Early indicators of patient's benefit will be surrogate parameters which correlate only weakly with the desired endpoints. After the innovation has been in use, there will be more evidence on correlations between surrogate parameters and the desired endpoints to provide evidence of the patient benefit. From an administrative perspective, this evidence can be considered in decisions about public financing. Different criteria are proposed for the assessment of innovations in prevention, diagnosis and therapy. For decisions on public financing a public fund for innovations may be helpful. Depending on the phase of innovation risk sharing models are proposed between manufacturers, private insurers and public funding.

Summary: Potential for patient benefit is always uncertain during early stages of innovations. This uncertainty decreases with increasing information on the effects of the innovation. Information about an innovation can be quantified, categorized and integrated into rational economic decisions.

Show MeSH
The expectation-uncertainty-diagram of innovations. Positive expectations in an innovation as well as uncertainty of data (as assessed by validity and variance of results) are rated on a scale ranging from zero to 1. Four possible results are shown. Red dot: Too positive expectations but too much uncertainty; this constellation is not considered as innovation. Mixed colour dots: The green/yellow innovation is ranked higher than the red/yellow innovation because less positive expectation combined with less uncertainty is higher ranked than more positive expectation combined with more uncertainty. Green dot: the combination of positive expectation with low uncertainty is considered as innovation. T: threshold.
© Copyright Policy - open-access
Related In: Results  -  Collection

License
getmorefigures.php?uid=PMC2666677&req=5

Figure 1: The expectation-uncertainty-diagram of innovations. Positive expectations in an innovation as well as uncertainty of data (as assessed by validity and variance of results) are rated on a scale ranging from zero to 1. Four possible results are shown. Red dot: Too positive expectations but too much uncertainty; this constellation is not considered as innovation. Mixed colour dots: The green/yellow innovation is ranked higher than the red/yellow innovation because less positive expectation combined with less uncertainty is higher ranked than more positive expectation combined with more uncertainty. Green dot: the combination of positive expectation with low uncertainty is considered as innovation. T: threshold.

Mentions: These three components can be allocated to two dimensions which we believe are appropriate to classify innovations. The two dimensions concern the positive perspective and the uncertainty about expected risks and benefits (Fig. 1).


Qualitative assessment of innovations in healthcare provision.

Porzsolt F, Ghosh AK, Kaplan RM - BMC Health Serv Res (2009)

The expectation-uncertainty-diagram of innovations. Positive expectations in an innovation as well as uncertainty of data (as assessed by validity and variance of results) are rated on a scale ranging from zero to 1. Four possible results are shown. Red dot: Too positive expectations but too much uncertainty; this constellation is not considered as innovation. Mixed colour dots: The green/yellow innovation is ranked higher than the red/yellow innovation because less positive expectation combined with less uncertainty is higher ranked than more positive expectation combined with more uncertainty. Green dot: the combination of positive expectation with low uncertainty is considered as innovation. T: threshold.
© Copyright Policy - open-access
Related In: Results  -  Collection

License
Show All Figures
getmorefigures.php?uid=PMC2666677&req=5

Figure 1: The expectation-uncertainty-diagram of innovations. Positive expectations in an innovation as well as uncertainty of data (as assessed by validity and variance of results) are rated on a scale ranging from zero to 1. Four possible results are shown. Red dot: Too positive expectations but too much uncertainty; this constellation is not considered as innovation. Mixed colour dots: The green/yellow innovation is ranked higher than the red/yellow innovation because less positive expectation combined with less uncertainty is higher ranked than more positive expectation combined with more uncertainty. Green dot: the combination of positive expectation with low uncertainty is considered as innovation. T: threshold.
Mentions: These three components can be allocated to two dimensions which we believe are appropriate to classify innovations. The two dimensions concern the positive perspective and the uncertainty about expected risks and benefits (Fig. 1).

Bottom Line: From the patient's perspective, benefit resulting from an innovation can be confirmed only in a later phase of development.Potential for patient benefit is always uncertain during early stages of innovations.This uncertainty decreases with increasing information on the effects of the innovation.

View Article: PubMed Central - HTML - PubMed

Affiliation: Clinical Economics, University of Ulm, Frauensteige 6, 89075 Ulm, Germany. franz.porzsolt@uniklinik-ulm.de

ABSTRACT

Background: The triad of quality, innovation and economic restraint is as important in health care as it is in the business world. There are many proposals for the assessment of quality and of economic restraints in health care but only a few address assessment of innovations. We propose a strategy and new structures to standardize the description of health care innovations and to quantify them.

Discussion: Strategy and structure are based on the assumption that in the early phase of an innovation only data on the feasibility and possibly on the efficacy or effectiveness of an innovation can be expected. From the patient's perspective, benefit resulting from an innovation can be confirmed only in a later phase of development. Early indicators of patient's benefit will be surrogate parameters which correlate only weakly with the desired endpoints. After the innovation has been in use, there will be more evidence on correlations between surrogate parameters and the desired endpoints to provide evidence of the patient benefit. From an administrative perspective, this evidence can be considered in decisions about public financing. Different criteria are proposed for the assessment of innovations in prevention, diagnosis and therapy. For decisions on public financing a public fund for innovations may be helpful. Depending on the phase of innovation risk sharing models are proposed between manufacturers, private insurers and public funding.

Summary: Potential for patient benefit is always uncertain during early stages of innovations. This uncertainty decreases with increasing information on the effects of the innovation. Information about an innovation can be quantified, categorized and integrated into rational economic decisions.

Show MeSH